Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences

Theoretical and Natural Science

Vol. 24, 20 December 2023

Open Access | Article

Brain-targeted delivery of CRISPR/Cas9 mediated glioblastoma therapeutics

Sixie Liu * 1
1 Merck Chemicals (Shanghai) Co Ltd.

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 24, 99-105
Published 20 December 2023. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Sixie Liu. Brain-targeted delivery of CRISPR/Cas9 mediated glioblastoma therapeutics. TNS (2023) Vol. 24: 99-105. DOI: 10.54254/2753-8818/24/20231115.


Glioblastoma multiforme (GBM) is a life-threatening malignant tumor of the central nervous system, for which there is currently no effective treatment. Its low survival rate has been interpreted as a result of its high proliferation rate, resistance to apoptosis, and the ability to create a microenvironment conducive to tumor growth. Recently, a powerful and accurate gene-editing tool, Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-Associated Protein 9 (CRISPR/Cas9), has high potential in various scientific fields. Such technologies can manipulate cellular mechanisms and defective genes that lead to the progression of many serious diseases such as cancer. One of the major barriers to the application of this technique is the development of a delivery method to diffuse CRISPR/Cas9 efficiently and accurately to the target location in brain. Most existing delivery methods are failed to be translated into clinical result due to the lack of promising safety and efficiency. Thus, I will introduce several strategies here that can be used potentially for CRISPR-Cas9 system delivery in GBM treatment including the principle, advantages, limitations, and latest developments of these systems. This review is composed to provide a concise summary for future researchers to understand the current challenges and approaches in CRISPR/Cas9 mediated GBM therapeutics delivery.


glioblastoma, CRISPR, Cas9, drug delivery


1. Ostrom, Q. T. et al. (2022) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro-Oncol. 24, v1–v95 .

2. Ortensi, B., Setti, M., Osti, D. and Pelicci, G. (2013) Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res. Ther. 4, 18 .

3. Al-Sammarraie, N. and Ray, S. K. (2021) Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme. Cells 10, 2342 .

4. Ishino, Y., Shinagawa, H., Makino, K., Amemura, M. and Nakata, A. (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169, 5429–5433.

5. Mojica, F. J. M., Diez-Villasenor, C., Soria, E. and Juez, G. (2000) Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol. Microbiol. 36, 244–246 .

6. Mojica, F. J. M., Dez-Villaseor, C., Garca-Martnez, J. and Soria, E. (2005) Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements. J. Mol. Evol. 60, 174–182 .

7. Nakashima, H. et al. (2018) Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clin. Cancer Res. 24, 2574–2584 .

8. Warnock, J. N., Daigre, C. and Al-Rubeai, M. (2011) Introduction to Viral Vectors. in Viral Vectors for Gene Therapy (eds. Merten, O.-W. & Al-Rubeai, M.) vol. 737 1–25.

9. Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. and Gao, G. (2021) Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther. 6, 53 .

10. Hordeaux, J. et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol. Ther. 26, 664–668 .

11. Boucher, P., Cui, X. and Curiel, D. T. (2020) Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors. J. Controlled Release 327, 788–800 .

12. Atchison, R. W., Casto, B. C. and Hammon, W. McD. (1965) Adenovirus-Associated Defective Virus Particles. Science 149, 754–756 .

13. Matsushita, T. et al. (1998) Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938–945 .

14. Dong, J.-Y., Fan, P.-D. and Frizzell, R. A. (1996) Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus. Hum. Gene Ther. 7, 2101–2112 .

15. Alexander, J. J. and Hauswirth, W. W. (2008) Prospects for retinal cone-targeted gene therapy. Drug News Perspect. 21, 267 .

16. Schmidt, M. and Chiorini, J. A. (2006) Gangliosides Are Essential for Bovine Adeno-Associated Virus Entry. J. Virol. 80, 5516–5522.

17. Huang, L.-Y., Halder, S. and Agbandje-McKenna, M. (2014) Parvovirus glycan interactions. Curr. Opin. Virol. 7, 108–118 .

18. Bartlett, J. S., Samulski, R. J. and McCown, T. J. (1998) Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in Brain. Hum. Gene Ther. 9, 1181–1186 .

19. Cearley, C. N. and Wolfe, J. H. (2007) A Single Injection of an Adeno-Associated Virus Vector into Nuclei with Divergent Connections Results in Widespread Vector Distribution in the Brain and Global Correction of a Neurogenetic Disease. J. Neurosci. 27, 9928–9940.

20. Yamashita, T. et al. (2013) Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV 9‐ ADAR 2 delivery to motor neurons. EMBO Mol. Med. 5, 1710–1719.

21. Dayton, R. D., Wang, D. B. and Klein, R. L. (2012) The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin. Biol. Ther. 12, 757–766 .

22. Casaca-Carreira, J., Temel, Y., Hescham, S.-A. and Jahanshahi, A. (2018) Transependymal Cerebrospinal Fluid Flow: Opportunity for Drug Delivery? Mol. Neurobiol. 55, 2780–2788.

23. Davidson, B. L. et al. (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. 97, 3428–3432.

24. Fu, H. et al. (2003) Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol. Ther. 8, 911–917 .

25. Choi, B. D. et al. (2019) CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J. Immunother. Cancer 7, 304.

26. Colella, P., Ronzitti, G. and Mingozzi, F. (2018) Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol. Ther. - Methods Clin. Dev. 8, 87–104.

27. Raposo, G. and Stoorvogel, W. (2013) Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383.

28. Duan, L. et al. (2021) Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale 13, 1387–1397.

29. Sugahara, K. N. et al. (2009)Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors. Cancer Cell 16, 510–520.

30. Chen, Z. et al. (2017) Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles. Adv. Funct. Mater. 27, 1703036.

31. Liu, J. et al. (2022) ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage. Nat. Commun. 13, 2196.

32. Chang, H., Zhang, J., Wang, H., Lv, J. and Cheng, Y. A (2017) Combination of Guanidyl and Phenyl Groups on a Dendrimer Enables Efficient siRNA and DNA Delivery. Biomacromolecules 18, 2371–2378 .

33. Tabujew, I. et al. (2014) The Guanidinium Group as a Key Part of Water-Soluble Polymer Carriers for siRNA Complexation and Protection against Degradation. Macromol. Rapid Commun. 35, 1191–1197.

34. Hashim, P. K., Okuro, K., Sasaki, S., Hoashi, Y. and Aida, T. (2015) Reductively Cleavable Nanocaplets for siRNA Delivery by Template-Assisted Oxidative Polymerization. J. Am. Chem. Soc. 137, 15608–15611.

35. Ruan, W. et al. (2022) Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy. J. Controlled Release 351, 739–751.

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
ISBN (Print)
ISBN (Online)
Published Date
20 December 2023
Theoretical and Natural Science
ISSN (Print)
ISSN (Online)
20 December 2023
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated